Implications of Culture-Independent Panel Based Detection of *Cyclospora cayetanensis*

Sarah N. Buss¹,², #, Roxanne Alter¹, Peter C. Iwen¹,² and Paul D. Fey¹

¹Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska, USA

²Nebraska Public Health Laboratory, Omaha, Nebraska, USA

# Corresponding author. Mailing address: University of Nebraska Medical Center, 95900 Nebraska Medical Center, Omaha, NE 68198-5900. E-mail: sarah.buss@unmc.edu

The Nebraska Medical Center (TNMC) was conducting an Institutional Review Board approved research study utilizing the BioFire FilmArray Gastrointestinal Panel (BioFire Diagnostics, Salt Lake City, UT) when an outbreak of cyclosporiasis occurred in Iowa and Nebraska (1). The FilmArray GI Panel is a culture-independent molecular test that simultaneously detects 14 bacterial, 5 viral, and 4 protozoal targets (including *Cyclospora cayetanensis*) directly from stool specimens, irrespective of physician ordering practices or laboratory ordering policies. For the research study, de-identified residual stool specimens, originally submitted to the laboratory based on a health care provider’s suspicion of gastrointestinal illness, were tested with the FilmArray GI Panel. All specimens were tested fresh (not frozen) and within 4 days of the collection date.

In the clinical microbiology laboratory, *Cyclospora* testing is typically conducted using a specifically ordered, modified acid fast stained fecal smear. Prior to recognition and during the early stages of the cyclosporiasis outbreak, de-identified specimens that tested positive for *Cyclospora* using the FilmArray GI Panel in the research study were undetected by the clinical
laboratory because modified acid fast staining was not ordered. In total, *Cyclospora* was detected by the FilmArray GI Panel in 19 de-identified specimens collected between 18 June and 25 July 2013. As shown in Table 1, *Cyclospora* testing was not ordered for 8 of these specimens; three that were collected before the outbreak became known (prior to 28 June), and five that were collected early in the outbreak investigation (prior to 13 July). Importantly, the first *Cyclospora* positive specimen detected in our study was collected on 18 June, one week prior to the first reported positive case in Nebraska, and three days prior to the first reported positive case in Iowa (2). As the medical community became aware of the outbreak, direct analysis of stools for *Cyclospora* became a common practice, and stool specimens enrolled in the clinical study later in the outbreak timeline were more likely to have had *Cyclospora* testing ordered (Table 1). Our results indicate that routine utilization of the FilmArray GI Panel as a screening tool would have led to more rapid detection of the cyclosporiasis outbreak, since *Cyclospora* would have been detected before anyone was specifically looking for this parasite.

There are recognized challenges associated with the utilization of culture-independent molecular testing and the concomitant need for isolation of enteric bacteria required for further public health characterization or antimicrobial susceptibility testing (3). Our experiences during a *Cyclospora* outbreak however showed that culture independent technologies have the potential to positively impact the detection and management of patients with infectious diseases. Isolates are invaluable resources to public health surveillance and outbreak investigations, and clinical laboratories should not abandon the practice of obtaining isolates whenever appropriate. Accordingly, our laboratory personnel look forward to utilizing the FilmArray GI Panel as a screening tool for enteric pathogens (upon FDA clearance of the product) and plan to reflex positive specimens to culture or other isolation procedures when applicable. We believe that
appropriate laboratory implementation strategies are essential to ensure that culture independent technologies are used to elevate our capabilities and enhance public health surveillance.

Acknowledgements

This work was supported by NIH/NIAID grant RO1 AI 104593 and BioFire Diagnostics, Inc.

References


Table 1. Ordering practices related to the stool specimens positive for *Cyclospora* using the BioFire FilmArray GI Panel.\(^a\)

<table>
<thead>
<tr>
<th>Specimen collection date (in relation to outbreak)(^b)</th>
<th>Cyclospora Testing Ordered by Provider</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>YES</td>
</tr>
<tr>
<td>Before (before 28June)</td>
<td>0</td>
</tr>
<tr>
<td>Early (between 28June and 12July)</td>
<td>3</td>
</tr>
<tr>
<td>After established (after 12July)</td>
<td>8</td>
</tr>
</tbody>
</table>

\(^a\)For investigational use only.

\(^b\)The Centers for Disease Control and Prevention became aware of two domestically acquired, laboratory-confirmed cases of *Cyclospora* infection on 28June (1).